Drugmaker Eli Lilly has agreed to pay a $13.5 million settlement, ending a class-action lawsuit filed six years ago that alleged systemic overpricing of insulin. The company also agreed to continue its cap on users’ out-of-pocket costs for four years. The settlement still must be approved by the U.S. District Court for the District of New Jersey. A 2022 study in the Annals of Internal Medicine estimated that 1.3 million Americans ration their insulin because of the cost. #shorts #elililly #insulin #diabetes

свернуть